Online inquiry

IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14013MR)

This product GTTS-WQ14013MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL33 gene. The antibody can be applied in Chronic Obstructive Pulmonary Disease (COPD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq NM_001199640.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 90865
UniProt ID O95760
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ14013MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ556MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 4D5-8
GTTS-WQ15790MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ1681MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACZ885
GTTS-WQ3572MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ13604MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA R1450
GTTS-WQ11646MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MGD-013
GTTS-WQ5984MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CLLB8
GTTS-WQ11133MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MDX-1103
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW